South Korea-based Hyundai Bioscience, and the Drugs for Neglected Diseases initiative (DNDi), an international non-profi...
By partnering with Kyoto University in Japan, China Medical University (CMU) and Healthcare System in Taiwan has es...
The Ministry of Science and ICT and the Korea Research Institute of Bioscience and Biotechnology have announced the "Top...
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer treatments, has closed an oversubsc...
Japan's Chugai Pharmaceutical Co. has signed a collaboration agreement with GSK's Global Health Unit (GSK GH) for&n...
Chime Biologics has a vision to make biologics more accessible and affordable. How does this vision drive your day-to-da...
Cancer is inherently diverse, with significant variations both between different tumours and among individuals. This var...
Drug discovery is a lengthy and costly process, typically requiring billions of dollars and nearly a decade to bring a d...
Japan-based startup ThinkCyte, a biotechnology company pioneering novel artificial intelligence (AI)-based cell analysis...
AB2 Bio, a biotechnology company developing innovative therapies for the treatment of severe systemic hyperinflammatory ...
Japanese firm Renascience has concluded a joint research agreement on ageing with Prof. Douglas E. Vaughan, Direct...
Biophytis SA, a Paris-based clinical-stage biotechnology company specialising in the development of treatments for age-r...
South Korea's GI Innovation has signed a Memorandum of Understanding (MoU) with LaNova Medicines for the development of ...
GordonMD Global Investments LP, a US-based investment manager focused exclusively on global public and private biop...
BioMed X, an independent biomedical research institute based in Heidelberg, Germany, has announced the launch of a new c...
The Hong Kong University of Science and Technology (HKUST) has signed a Memorandum of Understanding (MoU) with Microsoft...
More than $4.3 million from the Health Research Council in New Zealand will allow University of Auckland researchers to ...
Australia-based Telix Pharmaceuticals has entered into an asset purchase agreement with US-based antibody engineering co...